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Background: A T cell costimulatory molecule with dipeptidyl peptidase IV (DPPIV) activity in its extracellular region,
CD26 is a multifunctional molecule associated with various proteins such as adenosine deaminase, caveolin-1,
CXCR4, collagen, and fibronectin, while playing an important role in the regulation of inflammatory responses and
tumor biology. We have focused on CD26 as a novel therapeutic target for various tumors and immune disorders,
and have developed a humanized anti-CD26 monoclonal antibody (mAb), YS110, which is currently being evaluated
in a phase I clinical trial for patients with CD26-expressing tumors, including malignant mesothelioma. Since
detection of tumor CD26 expression is required for determining potential eligibility for YS110 therapy, the
development of anti-human CD26 mAb that can clearly and reliably detect the denatured CD26 molecule in
the formalin-fixed paraffin-embedded tissues is critical.
Methods: To develop novel anti-CD26 mAbs capable of binding to the denatured CD26, we immunized mice with
CD26 protein denatured in urea buffer. After the fusion of splenocytes and myeloma cells, the mAbs were screened for
specific reactivity with human CD26 by flow cytometry, enzyme-linked immunosorbent assay, and immunohistochemistry.
The binding competitiveness of novel anti-CD26 mAbs with the humanized anti-CD26 mAb YS110 was also examined.
Results: We have succeeded in developing novel anti-human CD26 mAbs suitable for immunohistochemical staining
of CD26 in formalin-fixed tissue sections with reliable clarity and intensity. Importantly, some of these mAbs exhibit no
cross-reactivity with the humanized anti-CD26 mAb.
Conclusions: These novel mAbs are potentially useful as companion diagnostic agents to analyze CD26 expression in the
clinical setting while advancing future CD26-related research.
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CD26 is a 110-kDa type II membrane-bound glycopro-
tein with dipeptidyl peptidase IV (DPPIV) activity in its
extra cellular domain [1-3]. CD26 is composed of 766
amino acids (AAs), and is anchored to the lipid bilayer
by a single hydrophobic segment at residues 7–28. The
cytoplasmic tail of CD26 is composed of only 6 amino
acid residues at the N-terminal end (AA 1–6) without a
common signaling motif structure. The predominant
part of CD26 consists of the extra cellular domain (AA
29–766) divided into three regions, a glycosylated re-
gion, a cysteine-rich region and a C-terminal DPPIV
catalytic region [4,5]. DPPIV belongs to the serine prote-
ase family, able to cleave dipeptides from polypeptides
with N-terminal penultimate proline or alanine, and
regulates the activities of a number of cytokines and che-
mokines [3]. CD26 is a multifunctional molecule associ-
ated with various proteins such as adenosine deaminase
(ADA), caveolin-1, CXCR4, collagen, and fibronectin,
and is expressed on various cell types, including epithe-
lial cells (kidney proximal tubules, bile duct, prostate
and intestine), endothelial cells as well as T lymphocytes
[4-6]. The function of CD26 is dependent on cell types
and the microenvironment, which influence its multiple
biological roles [4-7].
In addition to being a marker of T cell activation,
CD26 is associated with T cell signal transduction pro-
cesses as a costimulatory molecule [4]. While CD26 ex-
pression is increased following activation of resting T
cells, CD4+CD26high T cells respond maximally to recall
antigens such as tetanus toxoid [8]. Moreover, crosslink-
ing of CD26 and CD3 with solid-phase immobilized
monoclonal antibodies (mAbs) can induce T cell costi-
mulation and IL-2 production by CD26+ T cells [4]. Fur-
thermore, high CD26 cell surface expression in CD4+ T
cells is correlated with the production of TH1-type cyto-
kines and high migratory activity [4]. Taking into ac-
count the data that effector T cells in inflamed lesions
express high levels of CD26, it is conceivable that
CD4+CD26+ T cells play an important role in the inflam-
matory process [5,9,10]. We have recently found that
cytotoxic activity of CD8+ T cells is also regulated via
CD26-mediated costimulation [11]. More recently, we
have shown that humanized anti-CD26 mAb appears to
be a promising novel therapy for the clinical control
of graft-versus-host disease (GVHD) in a xenogeneic
GVHD murine model [12]. CD26 is also expressed on
various tumors such as malignant mesothelioma, renal
carcinoma, colon cancer, hepatocellular carcinoma, lung
cancer, prostate cancer, gastrointestinal stromal tumor
(GIST), thyroid cancer, T-lymphoblastic lymphoma and
T-acute lymphoblastic leukemia [13]. We have shown
that administration of anti-CD26 mAb resulted in both
in vitro and in vivo inhibition of tumor cell growth,migration and invasion, and enhanced survival of mouse
xenograft models inoculated with T-lymphoma, renal
cell carcinoma or malignant mesothelioma [14-16].
Based on these findings, we have focused on CD26 as a
novel therapeutic target for various tumors and immune
disorders, and have developed a humanized anti-CD26
mAb, YS110, which is being investigated currently in a
phase I clinical trial for patients with CD26-expressing
tumors, including malignant mesothelioma [17].
The development of companion diagnostic agents to
be used in conjunction with the appropriate therapeutic
modalities is essential to maximize therapeutic effective-
ness while minimizing associated toxicities. Detection
of tumor CD26 expression is critical to determining
potential eligibility for treatment with humanized anti-
CD26 mAb, and it is also important to determine
whether CD26 expression on tumors or lymphocytes is
affected by anti-CD26 mAb therapy. Immunohistochem-
ical staining of CD26 with the many anti-CD26 mAbs
previously developed in our laboratory [18] did not
reveal an anti-CD26 mAb that can clearly detect the
denatured CD26 molecule in formalin-fixed paraffin-
embedded tissues. Meanwhile, testing of several commer-
cially available anti-CD26 mAbs designated as research
reagents for immunohistochemical staining, and a mAb
purchased from MBL indicated that these mAbs could
stain the denatured CD26 in formalin-fixed tissues, but
not with sufficient clarity. On the other hand, our testing
of commercially available anti-CD26 polyclonal antibodies
(pAbs), and a pAb purchased from R&D Systems showed
that these reagents exhibited reliable staining pattern and
intensity [19]. However, the disadvantage of pAbs is the
potential lot-to-lot variability in staining pattern and in-
tensity, which makes pAbs not the ideal reagents for diag-
nostic testing of patient specimens in the clinical setting,
where consistency and uniformity are required.
In the present study, by immunizing mice with CD26
protein denatured in urea buffer, we have succeeded in
developing novel anti-human CD26 mAbs that can be
used as companion diagnostic reagents suitable for im-
munohistochemical staining of CD26 in formalin-fixed
tissue sections with reliable clarity and intensity. In
addition, since some of these mAbs display no cross-
reactivity with the therapeutic humanized anti-CD26
mAb, they may be suitable for assays analyzing CD26
expression during or following treatment with the hu-
manized anti-CD26 mAb.Materials and methods
Animals
Female BALB/c mice were purchased from CLEA Japan
(Tokyo, Japan) and housed in a specific pathogen-free
facility in micro-isolator cages. Animal experiments were
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Care and Use Committee at Juntendo University.
Antibodies
To determine the epitope of the newly developed mouse
anti-human CD26 mAbs, murine anti-human CD26
mAbs (clone 4G8, 1F7, 14D10, 5F8, 16D4B or 9C11)
which have been already developed in our laboratory
were used [18]. We have previously shown that these
mAbs are divided into 5 separate groups by their epi-
topes, 4G8 recognizing the 1-247th AAs region of
CD26, 1F7 and 14D10 recognizing the 248-358th AAs
region of CD26, 5F8 recognizing the 359-449th (closer
to the 359th) AAs region of CD26, 16D4B recognizing
the 450-577th AAs region of CD26, and 9C11 recogniz-
ing the 359-653th (but different from 5F8 or 16D4B)
AAs region of CD26. The humanized anti-CD26 mAb
(YS110) was generated by utilizing the complementarity
determining regions of the murine anti-human CD26
mAb 14D10 [18], and generously provided by Y's Thera-
peutics (Tokyo, Japan). To compare the staining pattern
and intensity of human CD26 on formalin-fixed tissue
sections, we used two commercial anti-human CD26
Abs available for CD26 detection by immunohistochem-
istry. One is the culture supernatant form of a mouse
anti-human CD26 mAb (clone 44–4) purchased from
MBL (Nagoya, Japan), and the other is a purified goat
anti-human CD26 pAb purchased from R&D Systems
(Minneapolis, MN). Human polyclonal IgG (venilon-I)
was purchased from Alfresa Corporation (Tokyo, Japan),
and mouse IgG1 isotype control (clone MG1-45) was
purchased from BioLegend (San Diego, CA). YS110,
control human IgG, 4G8, 1F7, 5F8, 16D4B, 9C11, puri-
fied clone 18, clone 19, and mouse IgG1 isotype control
were labeled using an Alexa Fluor 647 Monoclonal Anti-
body Labeling Kit (Molecular Probes, Eugene, OR) ac-
cording to the manufacturer's instructions.
cDNA constructs and transfection
As described previously [18], C-terminal deletion mu-
tants of human CD26 cDNA constructs were generated
by using Nco I restriction enzyme sites to delete domain
representing the 740-766th AAs in the C terminus,
using Nhe I to delete from the 578th AA, using BspE I
to delete from the 450th AA, using Stu I to delete from
the 359th AA, and using Pst I to delete from the 248th
AA. These cDNAs were ligated in-frame into pcDL-SRα
expression vector [20]. The green fluorescence protein
(GFP)-expressing vector pEB6-CAG-GFP was a kind gift
from Dr. Yoshihiro Miwa (Tsukuba University, Tsukuba,
Japan) [21]. Each CD26 deletion construct in pcDL-SRα
was co-transfected with pEB6-CAG-GFP into COS-7
cells using Lipofectamine 2000 reagent (Invitrogen,
Carlsbad, CA). After 24 hours of transfection, cells wereharvested, followed by staining with Alexa Fluor 647-
labeled 4G8, 1F7, 5F8, YS110, clone 18 or clone 19, and
then analyzed by flow cytometry.
Preparation of immunogen
Soluble CD26 (sCD26) was produced according to the
method described previously [22]. Briefly, the expression
vector RcSRα-26d3-9, which contains a deletion of the
coding sequence for amino acids 3–9 of CD26, was
transfected into a dihydrofolate reductase deficit Chinese
hamster ovary (CHO) cell line, DXB-11 by electropor-
ation, together with pMT-2 providing the dihydrofolate
reductase gene. The transfected CHO cells were cul-
tured in serum-free CHO-S-SFM II medium (Invitrogen)
supplemented with 1 μM methotrexate (Nacalai Tesque,
Kyoto, Japan). The culture supernatant was collected
and subjected to affinity chromatography on ADA-
Sepharose according to the method described previously
[23]. Purified sCD26 was denatured in 8 M urea buffer
supplemented with 20 mM HEPES and 50 mM dithio-
threitol (DTT) by gentle rotation for 8 hours at RT.
Development of hybridomas and monoclonal anti-human
CD26 antibodies
Denatured sCD26 was dialyzed in PBS, and 100 μg of pro-
tein per 50 μl of PBS was emulsified with 50 μl of adjuvant,
TiterMax Gold (TiterMax USA, Norcross, GA). A 6-wk-
old female BALB/c mouse was immunized s.c. with 100 μl
of the emulsion seven times every two weeks and finally
injected i.v. with half volume of the emulsion. Three days
after the final immunization, the spleen was removed and
100 × 106 spleen cells were fused with 100 × 106 P3U1
myeloma cells by using polyethylene glycol 4000 (Merck,
Darmstadt, Germany) and were cultured in RPMI1640
supplemented with 10% fetal bovine serum (FBS, Japan
Bioserum, Fukuyama, Japan), 5% BriClone (NICB, Dublin,
Ireland) and HAT (Invitrogen) in 96-well flat-bottom
plates (Costar, Corning Incorporated, Corning, NY). Hy-
bridoma supernatants were screened for selective reactivity
with human CD26 by using flow cytometry and enzyme-
linked immunosorbent assay (ELISA). The supernatants
which can detect human CD26 by both flow cytometry
and ELISA were finally screened for immunostaining of
formalin-fixed paraffin-embedded human tissue sections.
The hybridomas were cloned by limiting dilution and cul-
ture medium was exchanged for serum-free GIT medium
(Wako Pure Chemicals, Osaka, Japan). Monoclonal anti-
bodies were purified from the supernatants using Protein
A IgG Purification Kit (Pierce, Rockford, IL) according to
the manufacturer’s instructions.
Flow cytometry
A CD26-negative Jurkat T cell line (Jurkat parent) and a
stable Jurkat T cell line transfected with human CD26
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used for screening of hybridomas. Cells were washed in
PBS containing 1% FBS, 1 mM EDTA and 0.1% sodium
azide, and incubated with 100 μl of hybridoma super-
natant or 20 μg/ml of purified mouse anti-human CD26
mAb for 25 min at 4°C, and subsequently stained with
PE-conjugated goat anti-mouse Ig pAb (BD Biosciences,
San Jose, CA) for 25 min at 4°C. Acquisition was per-
formed using FACSCalibur (BD Biosciences) and data
were analyzed with FlowJo software (Tree Star, Ashland,
OR). For cross-blocking studies of humanized anti-
CD26 mAb (YS110), cells were pretreated with un-
labeled YS110 or control human IgG (50 μg/ml, respect-
ively) for 25 min at 4°C, and subsequently incubated
with 100 μl of hybridoma supernatant or 20 μg/ml of
purified mouse anti-human CD26 mAb for 25 min at
4°C, and finally stained with PE-conjugated goat anti-
mouse Ig pAb for 25 min at 4°C. For cross-blocking
studies of murine anti-CD26 mAbs, cells were pretreated
with unlabeled 4G8, 1F7, 5F8, 16D4B, 9C11 or mouse
IgG1 isotype control (50 μg/ml, respectively) for 25 min
at 4°C, and subsequently stained with Alexa Fluor 647-
labeled clone 18 or clone 19 or PE-conjugated goat anti-
mouse Ig pAb for 25 min at 4°C.
ELISA
The 96-well immunoplates (NUNC, Roskilde, Denmark)
were coated with native sCD26 or denatured sCD26 de-
scribed above in carbonate bicarbonate buffer (200 ng/
well, respectively) or buffer alone as a negative control
at 4°C overnight. Each well of the plate was blocked with
3% bovine serum albumin (BSA, Sigma, St.Louis, MO)
in PBS for 1 hour at RT, and then incubated with 3-fold
diluted hybridoma supernatants or 5 μg/ml of purified
mouse anti-human CD26 mAb or goat anti-human
CD26 pAb for 1 hour at RT, and subsequently incubated
with horseradish peroxidase (HRP)-conjugated goat anti-
mouse Ig pAb (BD Biosciences) or HRP-conjugated
donkey anti-goat IgG Ab (Santa Cruz Biotechnology,
Santa Cruz, CA) for 1 hour at RT. Tetramethylbenzidine
(TMB) Peroxidase Substrate (KPL, Gaithersburg, MD)
was finally added to each well and the reaction was
stopped by 2N H2SO4. The absorbance at 450 nm/
570 nm was measured in a Microplate Reader (Bio-Rad,
Hercules, CA) and data were analyzed with Microplate
Manager 6 software (Bio-Rad).
Tissue specimens and immunohistochemical staining
Formalin-fixed paraffin-embedded tissue specimens of
malignant mesothelioma and normal liver, kidney and
prostate were used for positive controls in the immuno-
histochemical examination. The use of human sample
from autopsy cases with hepatocellular carcinoma, renal
cell carcinoma, prostate adenocarcinoma, colon adeno-carcinoma and lung adenocarcinoma was generously
permitted by the bereaved families. This study was ap-
proved by the Okayama Rosai Hospital ethical review
board and the Keio University School of Medicine eth-
ical review board, and the purpose of the study was
explained to all patients and their written informed con-
sent was obtained. All studies on human subjects were
carried out according to the principles set out in
the Declaration of Helsinki. Formalin-fixed paraffin-
embedded tissue specimens were cut into 4-6 μm
sections and deparaffinized. Antigen retrieval was per-
formed by 1) autoclaving in 10 mM citrate buffer
(pH 6.0) for 20 min at 120°C, 2) 0.05% trypsin for
15 min at 37°C, 3) 0.02% proteinase K for 10 min at
37°C, or 4) boiling in 10 mM citrate buffer (pH 6.0)
for 10 min at 100°C, and the sections were treated
with 0.3% H2O2 in methanol for 10 min at RT to inacti-
vate endogenous peroxidase, then treated with 2.5%
horse serum (Vector Laboratories, Burlingame, CA) for
10 min at RT to block non-specific binding of the sec-
ondary horse antibody. The sections were treated with
100 μl of hybridoma supernatants or purified mouse
anti-human CD26 mAb or goat anti-human CD26 pAb
for 2 hours at RT, and subsequently treated with HRP-
conjugated horse anti-mouse Ig pAb or HRP-conjugated
horse anti-goat IgG pAb (Vector Laboratories) for 30 min
at RT. The reaction was visualized with 3, 3’-diaminoben-
zidine (DAB) (Dojindo Laboratories, Kumamoto, Japan),
and the tissue sections were counterstained for nucleus
with hematoxylin. To confirm the binding specificity of
Abs to human CD26, the anti-human CD26 Ab (100 μg/
ml) was gently rotated with 500 μg/ml of sCD26 at 4°C
overnight, and after centrifugation, the supernatant was
used instead of the primary anti-human CD26 Ab. Expres-
sion pattern of CD26 was evaluated and verified independ-
ently by two pathologists. The optical microscope images
were taken using Axio Scope.A1 microscope (Carl Zeiss,
Oberkochen, Germany).
Results
Screening of hybridoma cells
To develop a novel anti-CD26 mAb capable of binding
to the denatured CD26, we immunized mice with CD26
protein denatured in urea buffer. To determine the de-
naturing condition, we incubated CD26 protein in 8 M
urea buffer at RT for 30 min, 3 hours or 12 hours, and
analyzed the binding of anti-CD26 mAb (clone 5F8) or
anti-CD26 pAb (R&D Systems) to the urea treated
CD26 protein by ELISA as described in Materials and
Methods. This analysis showed the decrease in the ab-
sorbance when CD26 protein was incubated for 30 min
in urea buffer, with additional decrease in absorbance at
3 hours of incubation, while there was barely noticeable
difference between 3 hours of incubation and 12 hours
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most of the CD26 proteins were denatured when incu-
bated in 8 M urea buffer for more than 3 hours, and we
used this urea-treated CD26 protein as an immunogen.
After the fusion of splenocytes and P3U1 myeloma
cells, the culture supernatant was collected and screened
for selective reactivity with human CD26. For the first
screening of hybridoma cells, we used an endogenous

































Figure 1 Flow cytometry analysis with novel anti-CD26 mAbs. A. Jurka
incubated with the hybridoma supernatant, and subsequently stained with
B. Jurkat-CD26WT cells were incubated with the hybridoma supernatant (c
or commercial mouse anti-CD26 mAb (MBL, clone 44–4), and subsequently
cytometry. The gray areas in each histogram show the data involving the i
is shown. Data shown are repeated twice (A) and five times (B) with similaJurkat cell line transfected with full-length human CD26
(Jurkat-CD26WT), and the binding to human CD26 was
analyzed by flow cytometry. As shown in Figure 1A, we
obtained a number of hybridomas secreting antibodies,
some of which could stain Jurkat-CD26WT with bright
intensity and others could stain with intermediate or
dull intensity (red lines) while Jurkat parent cells showed
no staining with all of these supernatants (blue lines).
These data indicate that this screening method excludes(44-4)
MFI 144
26
ne 5 clone 11





t-CD26WT cells (red lines) or Jurkat parent cells (blue lines) were
PE-labeled anti-mouse Ig pAb, and analyzed by flow cytometry.
lone 1, 5, 11, 16, 18 or 19) or purified mouse anti-CD26 mAb (5F8)
stained with PE-labeled anti-mouse Ig pAb, and analyzed by flow
sotype control. The mean fluorescence intensity (MFI) of each staining
r results.
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beside CD26. The representative histograms of these
novel anti-CD26 mAbs available for immunohistochemi-
cal staining were shown in Figure 1B.
The positive supernatants were then screened by
ELISA for reactivity with native or denatured (urea
treated) sCD26 protein. To exclude the possibility of
non-specific binding to BSA used for blocking, we
prepared the wells coated with buffer alone (without
sCD26), subsequently blocked with BSA and incubated
with hybridoma supernatants. The absorbance of the
wells at 450 nm was subtracted from the absorbance of
the wells coated with native or denatured sCD26. The
clone was judged to be positive if the absorbance to the
native sCD26 was higher than 0.1. The absorbance to
the native or denatured sCD26 was quite different from
clone to clone, and the representative absorbance of
novel anti-CD26 mAbs available for immunohistochemi-
cal staining was shown in Figure 2. When sCD26 was
denatured in urea buffer, the absorbance of 5F8, which
cannot detect denatured CD26 in formalin-fixed tissues,
was apparently decreased, while the absorbance of
commercial mAb (purchased from MBL) or pAb (pur-
chased from R&D Systems) was comparatively main-
tained (Figure 2). Although the decrease of absorbance
to the denatured sCD26 was also observed with the
novel anti-CD26 mAbs, particularly with clone 1, clone
11 and clone 16, the absolute value of absorbance to the
denatured sCD26 was much higher than that of 5F8, ex-
cept for clone 11 (Figure 2). As a result of the screening,
31 clones that secreted anti-human CD26 mAbs were




















1 5 11 16 18 19 5F8 MBL R&D
Native sCD26
Denatured sCD26
Figure 2 ELISA analysis with novel anti-CD26 mAbs. Non treated
native soluble CD26 (sCD26) or urea treated denatured sCD26 was
incubated with the hybridoma supernatant (clone 1, 5, 11, 16, 18 or 19)
or purified mouse anti-CD26 mAb (5F8) or commercial mouse anti-
CD26 mAb (MBL, clone 44–4) or purified goat anti-CD26 pAb (R&D
Systems). The absorbance at 450 nm/570 nm was measured, and data
are shown as mean ± S.E. from three independent experiments.Immunohistochemical staining with novel anti-CD26
mAbs
To determine whether the newly developed anti-CD26
mAbs were suitable for immunohistochemical staining
of CD26 in formalin-fixed tissue sections, surgically
resected tissue specimens of normal liver, kidney, pros-
tate, and malignant mesothelioma were immunostained
with these mAbs, with commercial anti-CD26 mAb
(purchased from MBL) and anti-CD26 pAb (purchased
from R&D Systems) being used as controls. Although
we examined several antigen retrieval conditions, tissue
specimens stained with anti-CD26 mAb purchased
from MBL exhibited only a slightly positive reaction
with weak staining intensity, revealing this mAb to be
inappropriate for the detection of CD26 expression in
formalin-fixed clinical samples (Figure 3A-i). In contrast,
tissue specimens stained with anti-CD26 pAb purchased
from R&D Systems exhibited a clear staining pattern of
CD26, namely the surface membrane of bile canaliculi,
the brush border of renal proximal tubular epithelial
cells and prostate epithelial cells were specifically stained
with low background (Figure 3A-ii). We have previously
shown that CD26 was also highly expressed in various
pathologic types of malignant mesothelioma, including
localized malignant mesothelioma, well-differentiated
papillary malignant mesothelioma, and diffuse malignant
mesothelioma [16], and the specific staining of malig-
nant meshothelioma cells was also observed with the
use of the anti-CD26 pAb (Figure 3A-ii). After testing
the hybridoma supernatants from the 31 clones de-
scribed above for immunohistochemical staining, we
finally obtained 6 clones (clone 1, 5, 11, 16, 18 or 19)
capable of staining CD26 in formalin-fixed tissues with
much stronger intensity than the mAb purchased from
MBL. As shown in Figure 3A, tissue specimens stained
with two representative clones (clone 18 or 19) exhibited
reliable staining pattern and intensity comparable to the
pAb purchased from R&D Systems (panels iii and iv),
while no apparent staining of CD26 was observed in the
specimens stained with clone 3 (judged to be negative
for immunostaining) (panel v). Representative results of
immunostaining with the other 4 clones (clone 1, 5, 11
or 16) were shown in Additional file 1: Figure S1.
We next examined immunohistochemical staining
with purified novel mAbs instead of the hybridoma
culture supernatants. To determine the optimal Ab
concentration for immunostaining, we evaluated the
anti-human CD26 Abs in concentrations ranging from
1 μg/ml to 100 μg/ml. As shown in Figure 3B, staining
of malignant mesothelioma cells was hardly observed
with 1 μg/ml of clone 18, clone 19 mAb or pAb pur-
chased from R&D Systems, while the staining intensity
was enhanced in a dose-dependent manner up to
































Figure 3 (See legend on next page.)
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Figure 3 Representative results of immunostaining with novel anti-CD26 mAbs. A. The tissue specimens of liver, kidney, prostate or two
cases of malignant mesothelioma were stained with 100 μl of commercial mouse anti-human CD26 mAb supernatant (MBL, clone 44–4) (i), or
10 μg/ml of purified goat anti-human CD26 pAb (R&D Systems) (ii), or newly developed hybridoma supernatant (clone 18 (iii), clone 19 (iv) or
clone 3 (v)). B. Malignant mesothelioma tissue specimens were stained with commercial goat anti-human CD26 pAb (R&D Systems) (i), or purified
novel mouse anti-human CD26 mAbs (clone 18 (ii) or clone 19 (iii)) at the indicated concentrations of Abs in the presence or absence of sCD26. C. The
tissue specimens of hepatocellular carcinoma, renal cell carcinoma, prostate adenocarcinoma, colon adenocarcinoma or lung adenocarcinoma were
stained with 100 μg/ml of commercial goat anti-human CD26 pAb (R&D Systems) (i), or purified mouse anti-human CD26 mAbs (clone 18 (ii) or clone























1 5 11 16 18 19 1F7 5F8 YS110
Figure 4 Analysis of crossreactivity of novel anti-CD26 mAbs
with humanized anti-CD26 mAb. Jurkat-CD26WT cells were
pretreated with unlabeled humanized anti-CD26 mAb (YS110) or
human control IgG, and then treated with the hybridoma supernatant
(clone 1, 5, 11, 16, 18 or 19) or purified mouse anti-CD26 mAb (1F7 or
5F8), and subsequently stained with PE-labeled anti-mouse Ig pAb. For
staining with humanized anti-CD26 mAb, cells were stained with Alexa
Fluor 647-labeled YS110 after pretreatment with unlabeled YS110.
Data were analyzed by flow cytometry, and the percentage of mean
fluorescence intensity (MFI) after YS110 blocking to MFI after control
IgG blocking is shown. Data shown are repeated twice with
similar results.
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centrations resulted in similar intensity as compared
with those stained with 100 μg/ml of the Abs (data not
shown). In addition, to confirm the binding specificity of
these Abs to human CD26, the sections were treated
with purified anti-human CD26 Ab preincubated with
sCD26. As shown in Figure 3B, the binding of these Abs
was completely inhibited by sCD26 (panels i, ii, iii).
These results indicate that the newly developed mAbs
specifically bind to human CD26, and 100 μg/ml seems
to be an optimal concentration of these Abs for immu-
nohistochemical staining.
We further examined immunohistochemical staining
of CD26-expressing tumor tissues other than malignant
mesothelioma (hepatocellular carcinoma, renal cell car-
cinoma, prostate adenocarcinoma, colon adenocarcin-
oma, and lung adenocarcinoma) with the purified mAb
of clone 18 or 19. As shown in Figure 3C, each tumor
tissue stained with clone 18 or 19 (panels ii and iii) ex-
hibited clarity and intensity similar to the levels observed
with the anti-CD26 pAb purchased from R&D Systems
(panel i). Results from the immunostaining studies indi-
cate that CD26 can be detected both on the cell surface
as well as cytoplasm of these carcinoma tissues.
Cross-blocking studies with humanized anti-CD26 mAb
In addition to detecting CD26 expression on tumor cells
or lymphocytes prior to the therapeutic administration
of humanized anti-CD26 mAb, it is also important to
evaluate whether anti-CD26 mAb therapy affects CD26
expression on relevant tissues. For this purpose, we next
examined the binding competitiveness of the 6 novel
anti-CD26 mAbs with the humanized anti-CD26 mAb
YS110. Jurkat-CD26WT was pretreated with unlabeled
YS110 or control human IgG for 25 min, subsequently
incubated with hybridoma supernatants, and stained
with PE-labeled anti-mouse Ig pAb. As shown in Figure 4
(representative histograms are shown in Additional file
1: Figure S2), binding of YS110 or 1F7 to CD26 was
completely blocked by YS110 while the binding of 5F8
to CD26 was hardly affected, indicating that YS110 was
sufficiently bound to CD26. Although binding of clone
1, 11, 16 or 19 to CD26 was hardly affected by YS110
pretreatment, binding of clone 5 was partially inhibited,and binding of clone 18 was completely inhibited by
YS110 (Figure 4 and Additional file 1: Figure S2). Taken
together, these data suggest that clone 19 was capable of
detecting denatured CD26 in formalin-fixed tissue sec-
tions with the most reliable staining pattern and inten-
sity, exhibited no cross-reactivity with YS110, and was
suitable for analysis of CD26 expression on clinical sam-
ples following the administration of YS110.
Epitope mapping of novel anti-CD26 mAbs
To define the CD26 epitope recognized by clone 18 and
19, we conducted cross-blocking studies using anti-
CD26 mAbs with epitopes that had been extensively
characterized previously as described in Materials and
Methods [18]. To confirm the binding of anti-CD26
mAbs to CD26, Jurkat-CD26WT was incubated with un-
labeled 4G8, 1F7, 5F8, 16D4B, 9C11 or mouse IgG1 iso-
type control for 25 min, and subsequently stained with
PE-labeled anti-mouse Ig pAb. As shown in Figure 5-i,
each anti-CD26 mAb was sufficiently bound to CD26
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control (red line). Modulation of cell surface CD26 into
the cytoplasm following treatment with these anti-CD26
mAbs did not occur under these experimental condi-
tions. Similarly, Jurkat-CD26WT was pretreated with
unlabeled anti-CD26 mAbs, and subsequently stained
with Alexa Fluor 647-labeled clone 18 or 19. As shown
in Figure 5, binding of clone 18 or 19 to CD26 was com-
pletely inhibited by 1F7 (panels ii) or 4G8 (panels iii), re-
spectively, with no effect by the other anti-CD26 mAbs.
These results suggest that the epitope defined by clone
18 might be identical to 1F7, locating between the 248-
358th AAs region of CD26, while the epitope defined by
clone 19 might be identical to 4G8, locating between the
1-247th AAs region of CD26.
For cross-blocking studies involving the other 4 novel
anti-CD26 mAbs, Jurkat-CD26WT was incubated with
unlabeled clone 1, 5, 11, 16, 18, 19 or mouse IgG1 iso-
type control for 25 min, and subsequently stained with
Alexa Fluor 647-labeled 4G8, YS110, 5F8, 16D4B or






























































Figure 5 Blocking experiment of novel anti-CD26 mAb binding to CD
anti-CD26 mAbs (4G8, 1F7, 5F8, 16D4B, or 9C11) (blue lines) or mouse IgG1
with PE-labeled anti-mouse Ig pAb (i) or Alexa Fluor 647-labeled anti-CD26
The representative histograms of CD26 expression are shown, and the gray
Data shown are repeated twice with similar results.of 4G8 to CD26 was completely blocked by clone 19,
and binding of YS110 to CD26 was completely inhibited
by clone 18 and partially inhibited by clone 5, consistent
with the results shown in Figures 4 and 5. Clone 1
blocked completely the binding of 9C11 and partially the
binding of 16D4B to CD26, while clone 16 completely
inhibited the binding of both 9C11 and 16D4B to CD26
(Additional file 1: Figure S3). On the other hand, clone
11 inhibited the binding of 5F8 to CD26 completely
(Additional file 1: Figure S3). These results strongly sug-
gest that the novel anti-CD26 mAbs have a wide range
of epitopes and can be broadly divided into 4 separate
groups; the epitope of clone 19 being similar to 4G8, the
epitopes of clone 5 and 18 being similar to 1F7 and
YS110, the epitope of clone 11 being similar to 5F8, and
the epitopes of clone 1 and 16 being similar to 9C11
(clone 16 is also similar to 16D4B).
To further confirm the epitope involved in binding of
clone 18 and 19 to human CD26, we tested the ability of
these two mAbs to bind to CD26 deletion mutants by flow


























































26. Jurkat-CD26WT cells were pretreated with unlabeled mouse
isotype control (Contl. IgG) (red lines), and subsequently stained
mAbs (clone 18 (ii) or clone 19 (iii)), and analyzed by flow cytometry.
areas in each histogram show the data involving the isotype control.
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confirm the expression pattern of CD26 deletion mutants
on COS-7 cells. As shown in Additional file 1: Figure S4,
4G8 recognized full-length CD26 and all 5 CD26 deletion
mutants while 1F7 or 5F8 lost the ability to recognize the
CD26 molecule with deletion from the 248th AA or from
the 359th AA, respectively, indicating that the expression
patterns of CD26 deletion mutants were identical to those
reported previously [18]. We then analyzed the binding of
YS110, clone 18 and clone 19 to the CD26 deletion mu-
tants. As shown in Figure 6 (representative histograms are
shown in Additional file 1: Figure S4), both YS110 and
clone 18 recognized full length CD26, the 1-739th AAs re-
gion of CD26, the 1-577th AAs region of CD26, the 1-
449th AAs region of CD26 and the 1-358th AAs region of
CD26, but lost the ability to recognize the CD26 molecule
with deletion from the 248th AA, suggesting that the se-
quence of the 248-358th AAs region on CD26 might be
important for binding of YS110 and clone 18. On the other
hand, clone 19 recognized full-length CD26 and all 5 CD26
deletion mutants, suggesting that the epitope defined by
clone 19 might be located between the 1-247th AA region
(Figure 6 and Additional file 1: Figure S4). YS110, clone 18
and clone 19 did not bind to COS-7 cells transfected with
vector alone (mock) (Figure 6 and Additional file 1: Figure
S4). Taken together, results from the cross-blocking studies
and those involving CD26 deletion mutants strongly sug-
gest that the epitope defined by clone 19 may be located
between the 1-247th AAs region, and the epitope defined
by clone 18 between the 248-358th AAs region, being
almost identical to YS110.
Discussion
Although anti-human CD26 mAbs which we have devel-


















Figure 6 Staining for CD26 expression on COS-7 cells transfected wit
deleted CD26 was cotransfected with GFP-expressing plasmid to COS-7 ce
labeled anti-CD26 mAbs (YS110, clone 18 or clone 19) or isotype control, a
among all acquired cells, the percentage of CD26 positive cells was analyzeclearly detect denatured CD26 in formalin-fixed paraffin-
embedded tissues, the anti-human CD26 pAb purchased
from R&D Systems is able to stain CD26 with reliable clar-
ity and intensity. However, it is of concern that the stain-
ing pattern and intensity may differ among different lots
of the anti-CD26 pAb. Since treatment with targeted
therapeutic agents depends on the ability to reliably detect
the appropriate targets on clinical samples, uniformity of
the diagnostic reagents is critical, suggesting that pAbs
that are used as research reagents are not appropriate for
diagnostic uses in the clinical setting. In the present study,
we describe the successful development of novel anti-
human CD26 mAbs by immunizing mice with CD26 pro-
tein denatured in urea buffer that can potentially be used
as diagnostic reagents clinically.
In an attempt to improve diagnostic accuracy, markers
used for immunohistochemistry have been studied, such
as galectin-3, HBME-1 and CK-19 for diagnosis of
benign and malignant thyroid lesions [25,26], and FAP-α
and Calponin for diagnosing whether ductal carcinoma
in situ has microinvasion [27]. CD26 is highly expressed
on the surface of malignant mesothelioma cells espe-
cially tumors of the epitheloid and biphasic types, but
not on benign mesothelial tissues [16,17]. It has been re-
cently reported that the expression level of CD26 in
prostate cancer tissues is higher than that of normal
prostatic tissues and increased with prostate cancer stage
advancement, and CD26 expression is correlated with
prostate specific antigen, suggesting that CD26 may be a
good marker for prostate cancer diagnosis [28]. Further-
more, the overall survival of patients with CD26-positive
GISTs is worse than that of patients with CD26-negative
GISTs, suggesting that CD26 appears to be a reliable
biomarker of malignant GIST of the stomach [29]. These








h CD26 deletion mutants by novel anti-CD26 mAbs. cDNA of
lls. After 24 h, the transfected cells were stained with Alexa Fluor 647-
nd analyzed by flow cytometry. Following gating for GFP positive cells
d. Data shown are repeated twice with similar results.
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portant for diagnosis and prognosis of various tumors.
Since several anti-human CD26 mAbs such as Ta1,
1F7, 5F8 and 14D10 that were already developed in our
laboratory by immunizing mice with a CD26 positive
human T cell line (EL156) or a PHA-stimulated Aotus
trivirgatus T cell line or a murine pre-B human CD26
transfectant (300–19) cannot clearly detect CD26 in
formalin-fixed tissues [1,8,18], it was our hypothesis that
utilizing human CD26 protein but not human CD26
positive cells as an immunogen would be important for
the development of mAbs capable of recognizing the de-
natured CD26 molecule. Similar to CD26, only pAbs
could react to the denatured HLA class I molecules in
formalin-fixed paraffin-embedded tissues. Torigoe et al.
recently succeeded in developing a novel anti-pan HLA
class I mAb suitable for immunohistochemical staining
of fixed tissues by immunizing a recombinant HLA-A
protein denatured in urea buffer [30]. The exact role
played by urea treatment of the CD26 protein in
expanding the repertoire of the obtained anti-CD26
mAs is not yet clear, since we have not examined for po-
tential differences in the characteristics of mAbs ob-
tained after immunizing mice with urea-treated sCD26
protein or non-treated native sCD26 protein in this
study. However, as shown in Figures 2 and 3, tissue
specimens stained with anti-CD26 mAb purchased from
MBL exhibited only a partially positive reaction with
weak staining intensity, while this mAb showed higher
absorbance to the urea treated sCD26 protein than the
absorbance obtained from the novel anti-CD26 mAbs
capable of staining CD26 with strong intensity in fixed
tissues. These data strongly suggest that the structure of
CD26 denatured by the method of antigen retrieval after
formalin-fixation is quite different from that of CD26 de-
natured by urea buffer, and also suggest that anti-CD26
mAbs suitable for immunohistochemistry may be ob-
tained more efficiently by immunizing mice with CD26
protein denatured by methods other than urea treatment,
such as treatment with guanidine hydrochloride or sodium
dodecyl sulfate (SDS), or with proteases such as trypsin or
proteinase K, or by boiling. Further studies are needed to
clarify the issue involving pretreatment of the immuno-
gens and the characteristics of mAbs obtained after
immunization.
In the present study, we have succeeded in developing
novel anti-CD26 mAbs with a wide range of epitopes
(Figures 5, 6 and Additional file 1: Figure S3). Since most
of these novel mAbs completely inhibited the binding of
the anti-CD26 mAbs (4G8, 1F7, 5F8, 16D4B or 9C11)
developed previously by our group, the epitopes defined
by these novel mAbs are expected to be similar to those
recognized by the earlier mAbs. However, these novel
anti-CD26 mAbs are capable of detecting denaturedCD26 in fixed tissues with strong intensity, unlike the
previously developed mAbs. Similarly, while clone 18
and YS110 recognize the similar epitope on CD26
(Figure 4, Additional file 1: Figure S2 and Additional file
1: Figure S3), only clone 18 can stain CD26 clearly in fixed
tissues with strong intensity, suggesting that slight differ-
ences in the recognized epitopes can determine whether
mAb binding to its denatured antigen can occur.
Cross-blocking studies showed that, in contrast to
clone 5 or 18, the binding of clone 1, 11, 16 or 19 to
CD26 was hardly affected by the humanized anti-CD26
mAb YS110 (Figure 4, Additional file 1: Figure S2 and
Additional file 1: Figure S3), suggesting that these 4
novel anti-CD26 mAbs are suitable for analyzing CD26
expression in clinical samples following YS110 therapy.
Potential uses of these novel mAbs in the clinical setting
may be to detect CD26 expression in formalin-fixed tis-
sues, or on circulating cells in blood samples, or sCD26
levels in bodily fluids through such methods as immuno-
histochemistry, flow cytometry, or ELISA. Furthermore,
these novel mAbs are potentially useful for analyzing
CD26 expression in fixed tissues or on the surface of
lymphocytes or tumors during or following the adminis-
tration of humanized anti-CD26 mAb in animal disease
models that involve inoculated human lymphocytes or
tumors [12,16], and are expected to contribute to future
CD26-related research effort.
Since we intend to utilize these novel anti-CD26 mAbs as
companion diagnostic agents in the clinical setting, our
current effort is focused on improving immunohistochemi-
cal staining methods by examining such issues as the con-
dition of antigen retrieval or blocking, or the optimal
concentration of the primary antibody (anti-CD26 mAb)
that can maximize staining intensity while lowering back-
ground staining. Furthermore, we also identified the amino
acid sequence of the variable region in both the heavy chain
and light chain of clone 19 (data not shown), and will aim
to refine the ability of this mAb to bind to CD26 through
genetic engineering techniques.
In conclusion, we have succeeded in developing novel
anti-human CD26 mAbs suitable for immunohistochem-
ical staining of CD26 in formalin-fixed tissue sections
with reliable clarity and intensity. Furthermore, since
some of these mAbs exhibit no cross-reactivity with the
therapeutic humanized anti-CD26 mAb, they are poten-
tially useful as companion diagnostic agents in the
clinical setting while advancing future CD26-related
research.
Additional file
Additional file 1: Figure S1. Representative results of immunostaining
with novel anti-CD26 mAbs. The tissue specimens of liver, kidney,
prostate or two cases of malignant mesothelioma were stained with
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http://www.diagnosticpathology.org/content/9/1/30the hybridoma supernatant (clone 1, 5, 11 or 16), counterstained with
hematoxylin (original magnification, 200X). Figure S2. Analysis of
crossreactivity of novel anti-CD26 mAbs with humanized anti-CD26
mAb. Jurkat-CD26WT cells were pretreated with unlabeled humanized
anti-CD26 mAb (YS110) (blue lines) or human control IgG (red lines), and
then treated with the hybridoma supernatant (clone 1, 5, 11, 16, 18 or 19)
or purified mouse anti-CD26 mAb (1F7 or 5F8), and subsequently stained
with PE-labeled anti-mouse Ig pAb, or stained with Alexa Fluor 647-
labeled YS110. Data were analyzed by flow cytometry, and the
representative histograms are shown. The gray areas in each histogram
show the data of isotype control. Figure S3. Blocking experiment of
novel anti-CD26 mAb binding to CD26. Jurkat-CD26WT cells were
pretreated with the hybridoma supernatant (clone 1, 5, 11, 16, 18 or 19)
(blue lines) or mouse IgG1 isotype control (Contl. IgG) (red lines), and
subsequently stained with Alexa Fluor 647-labeled anti-CD26 mAbs or
PE-labeled anti-mouse Ig pAb, and analyzed by flow cytometry. The
representative histograms are shown, and the gray areas in each
histogram show the data of isotype control. Data shown are repeated
twice with similar results. Figure S4. Staining for CD26 expression on
COS-7 cells transfected with CD26 deletion mutants by novel anti-CD26
mAbs. cDNA of deleted CD26 was cotransfected with GFP-expressing
plasmid to COS-7 cells. After 24 h, the transfected cells were stained with
Alexa Fluor 647-labeled anti-CD26 mAbs or isotype control, and analyzed
by flow cytometry. The representative histograms of Alexa Fluor 647 were
obtained by gating for GFP positive cells among all acquired cells, and
the gray areas in each histogram show the data of isotype control.
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